What’s the latest on sulphonylureas in the management of type 2 diabetes?
Sulphonylureas act by binding to sulphonylurea receptors and stimulating insulin secretion from pancreatic beta cells. This class of oral hypoglycaemic agents is still widely used in the management of type 2 diabetes in patients where lifestyle changes alone are insufficient. Although the older-generation sulphonylureas no longer have a place in therapy, the newergeneration sulphonylureas are a widely recognised choice, either as monotherapy, or in combination with insulin and/or other oral hypoglycaemic agents.
Keywords: sulphonylureas, glibenclamide, gliclazide, glipizide, glimepiride, chlorpropamide, type 2 diabetes